Back to results
US 2003/0157525 A1Published application
Novel human G-protein coupled receptor, HGPRBMY31, and variants and methods of use thereof
OwnerGabriel A. Mintier, Chandra S. Ramanathan +1inventors
InventorsGabriel A. Mintier, Chandra S. Ramanathan, John N. Feder
Life of this patent
Estimating the term…
Abstract
The present invention describes human G-protein coupled receptors (GPCRs) and their encoding polynucleotides. Also described are expression vectors, host cells, antisense molecules, and antibodies associated with the GPCR polynucleotides and/or polypeptides of this invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders or diseases associated with abnormal biological activity of GPCR are described, as are methods for screening for modulators, for example, agonists or antagonists, of GPCR activity and/or function.
Claims30
An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:
- PTA-3949, which is hybridizable to SEQ ID NO:1;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:
- PTA-3949, which is hybridizable to SEQ ID NO:1;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:
- PTA-3949, which is hybridizable to SEQ ID NO:1;
- (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:
- PTA-3949, which is hybridizable to SEQ ID NO:1;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No:
- PTA-3949, which is hybridizable to SEQ ID NO:
- 1, having GPCR activity;
- (f) an isolated polynucleotide comprising nucleotides 93 to 1010 of SEQ ID NO:
- 1, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 307 of SEQ ID NO:2 minus the start codon;
- (g) an isolated polynucleotide comprising nucleotides 90 to 1010 of SEQ ID NO:
- 1, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 307 of SEQ ID NO:2 including the start codon;
- (h) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1;
- (i) a polynucleotide encoding a polypeptide of SEQ ID NO:4, which is hybridizable to SEQ ID NO:3, having GPCR activity;
- (j) an isolated polynucleotide comprising nucleotides 4 to 966 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 321 of SEQ ID NO:4 minus the start codon;
- (k) an isolated polynucleotide comprising nucleotides 1 to 966 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 321 of SEQ ID NO:4 including the start codon;
- (l) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:3;
- and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(l), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
19 more elements
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No:
- PTA-3949;
- (b) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No:
- PTA-3949, having GPCR activity;
- (c) a polypeptide domain of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No:
- PTA-3949;
- (d) a polypeptide epitope of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No:
- PTA-3949;
- (e) a full length protein of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No:
- PTA-3949;
- (f) a polypeptide comprising amino acids 2 to 307 of SEQ ID NO:2, wherein said amino acids 2 to 307 comprising a polypeptide of SEQ ID NO:2 minus the start methionine;
- (g) a polypeptide comprising amino acids 1 to 307 of SEQ ID NO:2;
- (h) a full length protein of SEQ ID NO:4;
- (i) a polypeptide comprising amino acids 2 to 321 of SEQ ID NO:4, wherein said amino acids 2 to 321 comprising a polypeptide of SEQ ID NO:4 minus the start methionine;
- and
- (j) a polypeptide comprising amino acids 1 to 321 of SEQ ID NO:4.
13 more elements
An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:
- (a) a polynucleotide encoding a polypeptide of SEQ ID NO:2;
- (b) an isolated polynucleotide consisting of nucleotides 93 to 1010 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 307 of SEQ ID NO:2 minus the start codon;
- (c) an isolated polynucleotide consisting of nucleotides 90 to 1010 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 307 of SEQ ID NO:2 including the start codon;
- (d) a polynucleotide encoding the HGPRBMY39 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. PTA-3949;
- (e) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1;
- (f) a polynucleotide encoding a polypeptide of SEQ ID NO:4;
- (g) an isolated polynucleotide consisting of nucleotides 4 to 966 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 321 of SEQ ID NO:4 minus the start codon;
- (h) an isolated polynucleotide consisting of nucleotides 1 to 966 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 321 of SEQ ID NO:4 including the start codon;
- and
- (i) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:3.
7 more elements
An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:2 having GPCR activity;
- (b) a polypeptide domain of SEQ ID NO:2 having GPCR activity;
- (c) a full length protein of SEQ ID NO:2;
- (d) a polypeptide corresponding to amino acids 2 to 307 of SEQ ID NO:2, wherein said amino acids 2 to 307 consisting of a polypeptide of SEQ ID NO:2 minus the start methionine;
- (e) a polypeptide corresponding to amino acids 1 to 307 of SEQ ID NO:2;
- (f) a polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-3949;
- (g) a full length protein of SEQ ID NO:4;
- (h) a polypeptide corresponding to amino acids 2 to 321 of SEQ ID NO:4, wherein said amino acids 2 to 321 consisting of a polypeptide of SEQ ID NO:4 minus the start methionine;
- and
- (i) a polypeptide corresponding to amino acids 1 to 321 of SEQ ID NO:4.
7 more elements
A method of screening for candidate compounds capable of modulating the activity of a G-protein coupled receptor polypeptide, comprising:
- (a) contacting a test compound with a cell or tissue expressing the polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2 or SEQ ID NO:4;
- and
- (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide, wherein said candidate modulating compounds are useful for the treatment of a disorder.
Dependencies are inferred from the claim text.